UNSPSC 51161884: Sequifenadine

This classification denotes a serotonin antagonist and histamine-1 receptor antagonist with the molecular formula C22H27NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C7Q3TBR3FP, chemically known as 3-quinuclidinemethanol, alpha,alpha-di-o-tolyl- but more generally known as sequifenadine, which bears U.S. NIH Compound Identifier 42553. European Medicines Agency schedules Sequifenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10488MIG.

The term SEQUIFENADINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). SEQUIFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51161884 Sequifenadine is a Commodity code that in recent state and local procurement shows minimal direct activity aligned with the pharmaceutical ingredient itself; instead, the code appears in opportunities for naloxone (an opioid antagonist unrelated to sequifenadine) and broader generic multi-source pharmaceutical procurement frameworks. State and local governments use this code tier for acquisition of specific pharmaceutical products and active ingredients distributed through health departments, emergency management agencies, and cooperative purchasing alliances. Issuing bodies include county health departments, state procurement offices administering multistate cooperative agreements, and regional health systems seeking to stock emergency medical supplies and routine pharmaceutical inventories.

Recent opportunities center on two distinct procurement models. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple generic pharmaceutical and over-the-counter product contracts effective July 1, 2026, drawing from three authorized wholesalers and requiring vendors to certify cGMP and Drug Supply Chain Security Act compliance. Geographic activity is concentrated in Florida and Minnesota with multistate reach through MMCAP's cooperative framework; the source does not support additional state-level concentration patterns.